IMAGING OF THYROID CANCER WITH RADIOLABELED OCTREOTIDE

该项目将测试是否使用标准诊断方法， 新的临床环境将定位于其他难以捉摸的，分化良好的 40%或更多的患者患有甲状腺癌。 二十名患者 他们将被研究;他们将：以前被治疗得很好， 分化型甲状腺癌，常规检查无残留癌 除了他们的血清甲状腺球蛋白水平会升高。 通过放射性核素显像评价肿瘤残留情况 注射放射性药物111-In-奥曲肽后第2天。 当 如果可能，将在甲状腺功能减退状态下重复成像方法 看看这种方法是否能更灵敏地发现 癌的 图像上的脱落物将被确认为肿瘤， 超声、CT和/或活检/切除。以前的组织学模式 将审查切除的原发性和转移性肿瘤，以确定 这些图案将预测层析结果。

This project will test whether a standard diagnostic method used in a new clinical setting will locate otherwise elusive, well-differentiated thyroid cancers in 40% or more of affected patients. Twenty patients will be studied; they will: have been previously treated for well- differentiated thyroid cancer, have no residual cancer by conventional tests except that their serum thyroglobulin levels will be elevated. They will be evaluated the residual tumors by scintigraphic imaging one day after injection of the radiopharmaceutical, 111-In-octreotide. When possible, the imaging method will be repeated in the hypothyroid state to see whether this approach provides more sensitivity in finding the cancers. Abnormalities on the images will be confirmed as tumors by ultrasound, CT and/or biopsy/excision. Histologic patterns of previously exicised primary and metastatic tumors will be reviewed to determine if the patterns will predict the scintigraphic results.